AI In Clinical Trials Market Strategies, Drivers, Top Players, Segmentation Forecast 2024 To 2033

The ai in clinical trials market size has grown exponentially in recent years. It will grow from $4.74 billion in 2023 to $6.69 billion in 2024 at a compound annual growth rate (CAGR) of 41.1%. The growth in the historic period can be attributed to data accumulation in healthcare, computing power advancements, fda support for ai, rise of wearable devices, early ai algorithms development.

The ai in clinical trials market size is expected to see exponential growth in the next few years. It will grow to $26.77 billion in 2028 at a compound annual growth rate (CAGR) of 41.5%. The growth in the forecast period can be attributed to real-world data integration, ai-powered patient recruitment, ai-driven biomarker identification, ai-driven trial design optimization, continuous monitoring technology. Major trends in the forecast period include federated learning approaches, ai in adaptive trials, ai-supported outcome prediction, ai-driven drug development, ai-powered drug repurposing.

Market Overview -
AI in clinical trials refers to the application of artificial intelligence (AI) technologies and techniques in the planning, design, execution, and analysis of clinical trials. Clinical trials are rigorous research studies that evaluate the safety and effectiveness of medical interventions, such as new drugs, medical devices, or treatment protocols, in human subjects.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=11961&type=smp

AI In Clinical Trials Market Surges With The Escalating Incidence Of Chronic And Infectious Diseases
Rising incidences of chronic and infectious diseases are expected to propel the growth of the AI in clinical trials market going forward. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Artificial intelligence in clinical trials is helpful to develop various drugs for treating chronic diseases. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the rising incidences of chronic and infectious diseases are driving the growth of the AI in the clinical trials market.

Competitive Landscape -
Major companies operating in the ai in clinical trials market report are Intel, The International Business Machines Corporation (IBM), Koninklijke Philips N.V., ConcertAI, Saama Technologies LLC, Samaa Technologies, Owkin Inc., Numerate, Neuroute, AiCure, Ardigen, Unlearn AI, PathAI, Exscentia, Aitia Infotech Pvt Ltd., Euretos, VeriSIM Life, Envisagenics, NURITAs, BioSymetrics, BioAge Labs Inc, Trials.Ai, Pharmaseal, Caylx, IQVIA

Lantern Pharma Unveils Radr AI And ML Platform, Elevating Ai In Clinical Trials For Accelerated Medication Discovery
Technological advancements are a key trend gaining popularity in the AI in clinical trials market. Companies operating in the AI in clinical trials market are adopting new technologies to sustain their position in the market. For instance, in February 2023, Lantern Pharma, a US-based clinical-stage oncology company introduced its unique RADR artificial intelligence ('AI') and machine learning ('ML') platform to revolutionize the expense, speed, and timeframe of oncology medication discovery and development. These RADR developments would concentrate on additional cutting-edge AI and ML methods to create antibody-drug conjugates (ADCs), which are highly targeted antibodies for the treatment of cancer that are connected to effective anti-tumor small molecules.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/ai-in-clinical-trials-global-market-report

Key Segments -

The ai in clinical trials market covered in this report is segmented -

1) By Offering: Software, Services
2) By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring
3) By Technology: Machine Learning, Deep Learning, Supervised Learning, Other Technologies
4) By Application: Oncology, Neurological Diseases And Condition, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Immunology diseases, Other Applications
5) By End-User: Pharmaceuticals And Biotechnology Companies, Contract Research Organizations, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.